Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of L04TD3 and L04RD1 in Healthy Volunteers
NCT05993806Phase 1Completed
- Sponsor
- Celltrion
- Start
- Jun 2023
- Primary completion
- Jun 2023
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of L04RD1 in essential hypertension (2 arms), sponsored by Celltrion. Primary endpoints: Area under the concentration-time curve from time 0 to the last measurable concentration at 48 hours and Maximum observed plasma concentration at 48 hours. Started Jun 2023; status: completed.
02
Drugs
L04RD1
03
Conditions
essential hypertension
Beyond the preview
Go deeper on NCT05993806.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05993806.